EUVIMEDEUVIMED entdecken
Crossref

Safety, tolerability and efficacy of the use of tixagevimab/cilgavimab as pre‐exposure COVID‐19 prophylaxis in kidney and simultaneous pancreas kidney transplant recipients

Wai H Lim, Jiayue Wang, Helen Pilmore, Stella McGinn, Anoushka Krishnan, Armando Teixeira-Pinto, Anh Kieu, Owen Ng, Germaine Wong iD

Internal Medicine Journal · 2025

DOI: 10.1111/imj.70179 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Wai H Lim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia. Hauptthemen laut MEDLINE: Kidney Transplantation, COVID-19, Pancreas Transplantation, Pre-Exposure Prophylaxis. Die Arbeit nennt 17 Literaturangaben. Gefördert von: AstraZeneca Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID‐19 pandemic resulted in high mortality rates in immunocompromised people, especially those who have received solid organ transplants. In this cohort of 540 transplant recipients who received tixagevimab/cilgavimab (Evusheld®) in Australia and New Zealand between January 2022 and January 2023, 11 (2%) Evusheld®‐treated recipients experienced moderate to severe COVID‐19 infection, with two deaths from COVID‐19 pneumonitis. Less than 0.5% experienced adverse events from Evusheld®. Prophylactic monoclonal antibody therapy may be considered an important adjunct to vaccination among immunocompromised patients to prevent severe infection during future viral outbreaks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationCOVID-19Pancreas TransplantationPre-Exposure ProphylaxisHumansMaleFemaleMiddle AgedAdultAgedNew ZealandAustraliaImmunocompromised HostAntibodies, Monoclonal, HumanizedTransplant RecipientsSARS-CoV-2

Stichwörter der Autor:innen

COVID‐19Evusheld®monoclonal antibodyprophylaxistixagevimab/cilgavimabtransplant

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
  • School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.
  • Medical School, University of Western Australia, Perth, Western Australia, Australia.
  • Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia.
  • Department of Renal Medicine, Auckland City Hospital, Auckland, New Zealand.
  • Department of Medicine, Auckland University, Auckland, New Zealand.

ORCID-Profile: Germaine Wong

Förderung

  • AstraZeneca Australia

Zitieren

APA

Lim, W. H., Wang, J., Pilmore, H., McGinn, S., Krishnan, A., Teixeira-Pinto, A., Kieu, A., Ng, O., & Wong, G. (2025). Safety, tolerability and efficacy of the use of tixagevimab/cilgavimab as pre‐exposure COVID‐19 prophylaxis in kidney and simultaneous pancreas kidney transplant recipients. Internal Medicine Journal. https://doi.org/10.1111/imj.70179

Vancouver

Lim WH, Wang J, Pilmore H, McGinn S, Krishnan A, Teixeira-Pinto A, et al. Safety, tolerability and efficacy of the use of tixagevimab/cilgavimab as pre‐exposure COVID‐19 prophylaxis in kidney and simultaneous pancreas kidney transplant recipients. Internal Medicine Journal. 2025. doi:10.1111/imj.70179

BibTeX
@article{Lim2025,
  author = {Lim, Wai H and Wang, Jiayue and Pilmore, Helen and McGinn, Stella and Krishnan, Anoushka and Teixeira-Pinto, Armando and Kieu, Anh and Ng, Owen and Wong, Germaine},
  title = {Safety, tolerability and efficacy of the use of tixagevimab/cilgavimab as pre‐exposure COVID‐19 prophylaxis in kidney and simultaneous pancreas kidney transplant recipients},
  journal = {Internal Medicine Journal},
  year = {2025},
  doi = {10.1111/imj.70179}
}
Kostenlos starten →